Oramed Pharmaceuticals Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Oramed Pharmaceuticals Inc. (ORMP) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2024Dec 2023Dec 2022Aug 2021Aug 2020Aug 2019Aug 2018
Operating Activities
Net Income-19.065.53-36.56-22.99-11.51-14.36-12.73
Depreciation & Amortization0.190.200.060.080.010.010.01
Stock Based Compensation4.054.2211.532.700.000.000.00
Change in Working Capital3.20-2.70-0.94-0.64-3.100.29-3.60
Change in Accounts Payable3.53-2.23-0.382.060.000.000.00
Change in Other Working Capital-0.330.870.141.040.000.000.00
Other Operating Activities-4.21-1.15-2.752.271.671.300.10
Net Cash from Operating Activities-8.41-10.30-27.92-21.18-12.44-12.94-14.66
Investing Activities
Capital Expenditures-0.02-0.25-0.500.380.080.020.00
Purchases of Investments105.90-72.7830.69-53.820.000.000.00
Sales/Maturities of Investments161.66118.14185.09-23.394.7111.27-7.00
Other Investing Activities-0.070.000.003.76-3.750.000.00
Net Cash from Investing Activities105.82-73.0430.21-23.764.6311.26-7.00
Financing Activities
Debt Repayment-49.55-50.000.000.000.000.000.00
Common Stock Issued0.002.4311.5679.980.000.0021.66
Common Stock Repurchased-2.490.00-0.780.000.000.000.00
Other Financing Activities0.00-0.78-0.781.500.000.000.00
Net Cash from Financing Activities-52.0451.9810.78102.8923.790.0022.65
Summary
Effect of Forex Changes on Cash0.00-0.05-0.060.000.000.010.03
Net Change in Cash45.37-31.4113.0157.9515.97-1.670.99
Cash at Beginning of Period9.0640.4627.4619.303.335.003.97
Cash at End of Period54.429.0640.4677.2519.303.335.00
Free Cash Flow-8.43-10.55-28.41-21.56-12.52-12.96-14.66
Supplemental Disclosures
Interest Paid2.320.570.000.000.000.000.00
Income Taxes Paid0.000.100.100.560.000.300.00